


# Product Information



## 19(20)-EpDPE

Catalog No. 10175

**Formal Name:** (±)19(20)-epoxy-4Z,7Z,10Z,13Z,16Z-docosapentaenoic acid  
**Synonym:** 19,20-epoxy Docosapentaenoic Acid  
**MF:** C<sub>22</sub>H<sub>32</sub>O<sub>3</sub>  
**FW:** 344.5  
**Purity:** ≥98%  
**Stability:** ≥1 year at -20°C  
**Supplied as:** A solution in ethanol



### Laboratory Procedures

For long term storage, we suggest that 19(20)-EpDPE be stored as supplied at -20°C. It should be stable for at least one year.

19(20)-EpDPE is supplied as a solution in ethanol. To change the solvent, simply evaporate the ethanol under a gentle stream of nitrogen and immediately add the solvent of choice. Solvents such as DMSO and dimethyl formamide purged with an inert gas can be used. The solubility of 19(20)-EpDPE in these solvents is approximately 50 mg/ml.

Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. If an organic solvent-free solution of 19(20)-EpDPE is needed, it can be prepared by evaporating the ethanol and directly dissolving the neat oil in aqueous buffers. The solubility of 19(20)-EpDPE in PBS (pH 7.2) is approximately 1 mg/ml. We do not recommend storing the aqueous solution for more than one day.

EDHF (endothelium-derived hyperpolarizing factor) is an unidentified mediator released from vascular endothelial cells in response to acetylcholine and bradykinin which is distinct from the NOS- (nitric oxide) and COX-derived (prostacyclin) vasodilators.<sup>1,2</sup> Cytochrome P450 (CYP450) metabolism of polyunsaturated fatty acids, produces epoxides such as 14(15)-EpETE which are prime candidates for the actual active mediator.<sup>3</sup> However, the CYP450 metabolites of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) have been little studied relative to arachidonate epoxygenase metabolites. 19(20)-EpDPE is a DHA epoxygenase metabolite, derived *via* epoxidation of the ω-3 double bond of DHA. The EDHF activity of 19(20)-EpDPE has not yet been determined. The epoxygenase metabolites of DHA have also been detected in a murine inflammation model.<sup>4</sup>

### References

1. Chataigneau, T., Félétou, M., Duhault, J., *et al.* Epoxyeicosatrienoic acids, potassium channel blockers and endothelium-dependent hyperpolarization in the guinea-pig carotid artery. *Br. J. Pharmacol.* **123**, 574-580 (1998).
2. Fisslthaler, B., Popp, R., Kiss, L., *et al.* Cytochrome P450 2C is an EDHF synthase in coronary arteries. *Nature* **401**, 493-497 (1999).
3. Baron, A., Frieden, M., and Bénay, J.-L. Epoxyeicosatrienoic acids activate a high-conductance, Ca<sup>2+</sup>-dependent K<sup>+</sup> channel on pig coronary artery endothelial cells. *J. Physiol.* **504**, 537-543 (1997).
4. Serhan, C.N., Hong, S., Gronert, K., *et al.* Resolvins: a family of bioactive products of ω-3 fatty acid transformation circuits by aspirin treatment that counter proinflammation signals. *J. Exp. Med.* **196(8)**, 1025-1037 (2002).

### Related Products

14(15)-EpETE - Cat. No. 10173 • 16(17)-EpDPE - Cat. No. 10174 • (±)5(6)-EpETE - Cat. No. 50211 • (±)8(9)-EpETE - Cat. No. 50351 • (±)14(15)-EpETE - Cat. No. 50651 • 17(18)-EpETE - Cat. No. 50861 • Docosahexaenoic Acid - Cat. No. 90310 • 4,5-epoxy Docosapentaenoic Acid methyl ester - Cat. No. 90314

**WARNING: THIS PRODUCT IS FOR LABORATORY RESEARCH ONLY: NOT FOR ADMINISTRATION TO HUMANS. NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.**

### MATERIAL SAFETY DATA

This material should be considered hazardous until information to the contrary becomes available. Do not ingest, swallow, or inhale. Do not get in eyes, on skin, or on clothing. Wash thoroughly after handling. This information contains some, but not all, of the information required for the safe and proper use of this material. Before use, the user must review the complete Material Safety Data Sheet, which has been sent *via* email to your institution.

### WARRANTY AND LIMITATION OF REMEDY

Cayman Chemical Company makes **no warranty or guarantee** of any kind, whether written or oral, expressed or implied, including without limitation, any warranty of fitness for a particular purpose, suitability and merchantability, which extends beyond the description of the chemicals hereof. Cayman **warrants only** to the original customer that the material will **meet our specifications at the time of delivery.**

Cayman will carry out its delivery obligations with due care and skill. Thus, in no event will Cayman have any **obligation or liability**, whether in tort (including negligence) or in contract, for any direct, indirect, incidental or consequential damages, even if Cayman is informed about their possible existence.

This limitation of liability does not apply in the case of intentional acts or negligence of Cayman, its directors or its employees. Buyer's **exclusive remedy** and Cayman's sole liability hereunder shall be limited to a **refund** of the purchase price, or at Cayman's option, the **replacement**, at no cost to Buyer, of all material that does not meet our specifications.

Said refund or replacement is conditioned on Buyer giving written notice to Cayman within thirty (30) days after arrival of the material at its destination. Failure of Buyer to give said notice within thirty (30) days shall constitute a waiver by Buyer of all claims hereunder with respect to said material.

For further details, please refer to our **Warranty and Limitation of Remedy** located on our website and in our catalog.

Copyright Cayman Chemical Company, 02/12/2010

## Cayman Chemical

### Mailing address

1180 E. Ellsworth Road  
Ann Arbor, MI  
48108 USA

### Phone

(800) 364-9897  
(734) 971-3335

### Fax

(734) 971-3640

### E-Mail

custserv@caymanchem.com

### Web

www.caymanchem.com